Invivyd, Inc.
For the period ended Aug 30, 2026. Filed Sep 1, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 30, 2026 · Filed Sep 1, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · About DECLARATION
About DECLARATION
DECLARATION is a Phase 3, randomized, triple-blind, placebo-controlled trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents both with and without risk factors for progression to severe COVID-19 at three months. Participants will receive either a single dose or monthly doses of VYD2311, each administered via intramuscular (IM) injection, compared to placebo. Total enrollment of the trial is approximately 2,400 participants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.